InSightec nets FDA approval for bone pain ultrasound therapy

Editorial Staff | | Health Imaging | Screening

The FDA has approved InSightec's ExAblate MRI guided focused ultrasound for treatment of painful bone metastases in patients who are not candidates for or refuse to undergo radiation treatment.

This is the second FDA approval for ExAblate, which received FDA approval in 2004 as a non-invasive, outpatient therapy for uterine fibroids. GE Healthcare is a minority shareholder of Insightec and is a distributor of ExAblate in many countries.

InSightec’s ExAblate system is exclusively compatible with GE Healthcare’s normal and wide-bore MR systems, including Signa HDxt 1.5T, Signa HDxt 3.0T, Optima MR450 & 450w and Discovery MR750 & 750w. It combines therapeutic acoustic ultrasound waves with guidance and treatment monitoring by MRI. This combination of technologies is called Magnetic Resonance guided Focused Ultrasound Therapy (MRgFUS). Physicians use the MRI to plan and guide the therapy and monitor treatment outcome. The focused ultrasound acoustic energy can destroy the nerves causing the pain from bone metastases, resulting in rapid reduction in pain, according to Insightec.

ExAblate also has received European CE marking for uterine fibroids, bone metastases and adenomyosis. ExAblate will be co-marketed by GE as InSightec’s distributor.

Editorial Staff

Related Content

What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.